Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Victorium Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$471,595

102 payments

Through program year 2025, Victorium Clinical Research is reported as receiving $471,595 in research payments, across 102 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $67,991 18
2024 Research $14,500 3
2023 Research $12,250 3
2022 Research $7,404 4
2021 Research $65,905 21
2020 Research $271,186 41
2019 Research $32,359 12

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $286,487 45 payments
  2. Alnylam Pharmaceuticals Inc. $59,341 11 payments
  3. Gilead Sciences, Inc. $28,783 6 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $25,110 11 payments
  5. Novo Nordisk AS $23,150 10 payments
  6. Biohaven Pharmaceuticals, Inc. $17,720 7 payments
  7. Vifor (International) Ltd. $12,000 3 payments
  8. F. Hoffmann-La Roche AG $11,750 5 payments
  9. Roche Diagnostics Operations, Inc. $7,254 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Phase 2A Hepatic Impairment $107,294 10 payments
  2. A Phase 2B Multicenter Randomized Doubleblind Placebocontrolled Doseranging Study to Evaluate the Efficacy Safety and Pharmacokinetics of Pf06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis $73,808 15 payments
  3. A 16Week Phase 2 Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin $60,327 7 payments
  4. Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $47,341 9 payments
  5. A 16Week Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Or Diet and Exercise $23,616 7 payments
  6. Nn9535-4352 $23,150 10 payments
  7. BAY94-8862 ph 3 conventional in diabetic nephropathy $19,610 9 payments
  8. A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention $15,825 6 payments
  9. A Phase 2B Randomized Doubleblind Parallelgroup Placebocontrolled Study With An Open Label Extension to Evaluate the Safety and Efficacy of Pf06826647 in Participants With Moderate to Severe Ulcerative Colitis $15,500 1 payment
  10. A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease $12,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record